Pharmaceutical giant Bristol Myers Squibb will invest $2.3 billion to build a 600,000-square-foot manufacturing facility at Generation Park in northeast Houston. The project is expected to create nearly 500 jobs and reflects the growing momentum behind Houston’s life sciences sector.
“As part of our $40 billion commitment to the United States, we’re building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs,” said Bristol Myers Squibb Board Chair and CEO Christopher Boerner, Ph.D. “Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life.”
According to a press release, BMS said the manufacturing facility will “be a modular, multi-modal campus,” allowing it to scale beyond its initial configuration to meet pipeline and commercial demands. BMS will manufacture multiple types of medicines, such as small molecules, biologics and antibody-drug conjugates. Construction of the facility is expected to begin in 2027 with operations slated to start in 2030.
The Partnership, alongside regional partners, played a key role in attracting the New Jersey-based biopharmaceutical company to the region.
“Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” said Greater Houston Partnership President and CEO Steve Kean.
Learn more about Houston’s life sciences and biotech ecosystem by connecting with the Partnership’s Global Life Sciences Sr. Director Verena Kallhoff.
Growing Investment in Houston’s Life Sciences Ecosystem
Last year, Eli Lilly and Company announced a $6.5 billion pharmaceutical manufacturing facility at Generation Park. Together, the projects reflect years of coordinated regional work to build the workforce, infrastructure and business environment needed to attract large-scale, for-profit life sciences investment. McCord Development, the developer of Generation Park, has played a central role in translating that regional strategy into a site prepared for major life sciences and biomanufacturing projects.
RELATED: Houston Wins Texas’ First Major Pharma Plant With $6.5B Investment
“We are grateful for this strong endorsement of Generation Park as a home for advanced life science manufacturing,” said Ryan McCord, CEO and President of McCord Development. “With beautiful parks, resilient infrastructure, higher education workforce development, and certainty of execution, Generation Park attracts jobs and supports the industry producing next-generation therapies.”
Why Houston
Houston competed against Indiana and North Carolina for this project. Houston offers a strong mix of research institutions, workforce training, available real estate and a business-friendly environment that supports companies at every stage of growth.
INSIDE THE STRATEGY: From Setback to Strategy: How San Jacinto College and Generation Park are Building Houston’s Biotech Workforce
The region is home to six medical schools, three Tier One research universities and specialized training programs through San Jacinto College’s NIBRT-licensed Center for Biotechnology, Lone Star College and Texas A&M’s National Center for Therapeutics Manufacturing. Houston has also attracted a growing roster of life sciences companies, from homegrown firms like Neurogene and CellReady to relocations including BioNova Scientific and Cellipont.
Discover why life sciences companies are choosing Houston.